CRL · Charles River Laboratories International
50 filings
CRL 10-Q Quarterly Reports
Charles River Laboratories International - 50 quarterly reports
CRL filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 118 current reports (8-K) between 2016 and 2026.
- 8-K · Jan 8, 2016
- 8-K · Jan 19, 2016
- 8-K · Feb 10, 2016
- 10-K · Feb 12, 2016
- 8-K · Mar 10, 2016
- 8-K · Apr 5, 2016
- 8-K · May 4, 2016
- 10-Q · May 4, 2016
- 8-K · May 16, 2016
- 8-K/A · May 16, 2016
- 8-K/A · Jun 15, 2016
- 10-Q · Aug 3, 2016
- 8-K · Aug 3, 2016
- 8-K · Nov 2, 2016
- 10-Q · Nov 2, 2016
- 8-K · Nov 2, 2016
- 8-K · Jan 10, 2017
- 10-K · Feb 14, 2017
- 8-K · Feb 14, 2017
- 8-K · Apr 26, 2017
- 8-K · May 10, 2017
- 10-Q · May 10, 2017
- 8-K · May 11, 2017
- 8-K · Jul 6, 2017
- 10-Q · Aug 9, 2017
- 8-K · Aug 9, 2017
- 8-K · Nov 9, 2017
- 10-Q · Nov 9, 2017
- 8-K · Nov 24, 2017
- 8-K · Jan 9, 2018
- 8-K · Jan 16, 2018
- 8-K · Feb 13, 2018
- 10-K · Feb 13, 2018
- 8-K · Feb 13, 2018
- 8-K · Feb 13, 2018
- 8-K · Mar 26, 2018
- 8-K · Apr 3, 2018
- 8-K · May 10, 2018
- 10-Q · May 10, 2018
- 8-K · May 14, 2018
- 8-K · Jun 14, 2018
- 8-K/A · Jun 14, 2018
- 10-Q · Aug 8, 2018
- 8-K · Aug 8, 2018
- 8-K · Aug 8, 2018
- 8-K · Aug 31, 2018
- 8-K · Oct 3, 2018
- 10-Q · Nov 7, 2018
- 8-K · Nov 7, 2018
- 10-K · Feb 13, 2019
- 8-K · Feb 13, 2019
- 8-K · Feb 15, 2019
- 8-K · Apr 30, 2019
- 8-K · May 1, 2019
- 10-Q · May 7, 2019
- 8-K · May 7, 2019
- 8-K · May 22, 2019
- 8-K · Jul 31, 2019
- 10-Q · Jul 31, 2019
- 8-K · Aug 2, 2019
- 8-K · Oct 1, 2019
- 8-K · Oct 21, 2019
- 8-K · Oct 23, 2019
- 10-Q · Nov 6, 2019
- 8-K · Nov 6, 2019
- 8-K · Feb 11, 2020
- 10-K · Feb 11, 2020
- 8-K · Mar 4, 2020
- 10-Q · May 7, 2020
- 8-K · May 7, 2020
- 8-K · May 8, 2020
- 8-K · Aug 5, 2020
- 10-Q · Aug 5, 2020
- 8-K · Oct 19, 2020
- 8-K · Oct 29, 2020
- 10-Q · Oct 29, 2020
- 10-K · Feb 17, 2021
- 8-K · Feb 17, 2021
- 8-K · Feb 17, 2021
- 8-K · Mar 9, 2021
- 8-K · Mar 23, 2021
- 8-K · Mar 29, 2021
- 8-K · Apr 23, 2021
- 10-Q · May 4, 2021
- 8-K · May 4, 2021
- 8-K · May 10, 2021
- 8-K · May 18, 2021
- 10-Q · Aug 4, 2021
- 8-K · Aug 4, 2021
- 10-Q · Nov 3, 2021
- 8-K · Nov 3, 2021
- 8-K · Nov 9, 2021
- 8-K · Nov 12, 2021
- 8-K · Dec 15, 2021
- 8-K · Dec 27, 2021
- 8-K · Jan 11, 2022
- 10-K · Feb 16, 2022
- 8-K · Feb 16, 2022
- 8-K · Mar 28, 2022
- 10-Q · May 4, 2022
- 8-K · May 4, 2022
- 8-K · May 12, 2022
- 8-K · Jun 8, 2022
- 8-K · Aug 3, 2022
- 10-Q · Aug 3, 2022
- 10-Q · Nov 2, 2022
- 8-K · Nov 2, 2022
- 8-K · Nov 30, 2022
- 8-K · Dec 6, 2022
- 10-K · Feb 22, 2023
- 8-K · Feb 22, 2023
- 8-K · May 11, 2023
- 10-Q · May 11, 2023
- 8-K · May 15, 2023
- 10-Q · Aug 9, 2023
- 8-K · Aug 9, 2023
- 10-Q · Nov 8, 2023
- 8-K · Nov 8, 2023
- 8-K · Nov 15, 2023
- 8-K · Jan 16, 2024
- 8-K · Jan 24, 2024
- 10-K · Feb 14, 2024
- 8-K · Feb 14, 2024
- 10-Q · May 9, 2024
- 8-K · May 9, 2024
- 8-K · May 10, 2024
- 8-K · Aug 7, 2024
- 10-Q · Aug 7, 2024
- 8-K · Nov 6, 2024
- 10-Q · Nov 6, 2024
- 8-K · Dec 13, 2024
- 8-K · Jan 14, 2025
- 10-K · Feb 19, 2025
- 8-K · Feb 19, 2025
- 8-K · Feb 21, 2025
- 8-K · May 7, 2025
- 10-Q · May 7, 2025
- 8-K · May 7, 2025
- 8-K · May 23, 2025
- 10-Q · Aug 6, 2025
- 8-K · Aug 6, 2025
- 8-K · Sep 16, 2025
- 8-K/A · Sep 19, 2025
- 8-K · Nov 5, 2025
- 10-Q · Nov 5, 2025
- 8-K · Nov 17, 2025
- 8-K · Dec 3, 2025
- 8-K · Jan 9, 2026
- 8-K · Jan 13, 2026
- 10-K · Feb 18, 2026
- 8-K · Feb 18, 2026
- 8-K · Feb 18, 2026
- 8-K · Feb 25, 2026
- 10-Q · May 7, 2026
- 8-K · May 7, 2026
- 8-K · May 11, 2026
- 10-Q · Aug 5, 2026
- 8-K · Aug 5, 2026
- 8-K · Sep 24, 2026
- 10-Q · Nov 4, 2026
- 8-K · Nov 4, 2026
- 8-K · Nov 9, 2026
- 2026-Q3Nov 4, 2026
Charles River Laboratories International Quarterly Report for Q3 Ended Sep 26, 2026
Charles River Laboratories International, Inc. reported third-quarter 2026 total revenue of $982.7 million, a decrease of $22.1 million, or 2.2%, from $1,004.9 million a year earlier. Nine-month revenue was $2,982.6 million versus $3,021.2 million, down 1.3%. The decline reflects the sale of the CDMO and Cell Solutions businesses and the European Discovery Services businesses, partly offset by growth in Microbial Solutions, Biologics Testing and regulated safety assessment. Operating income rose to $202.6 million (20.6% of revenue) for the quarter from $133.8 million (13.3%), and net income attributable to common shareholders increased to $333.1 million from $54.4 million, driven mainly by a $201 million tax benefit from the reversal of an unrecognized tax benefit reserve. Diluted EPS for the quarter was $6.86 versus $1.10. The nine-month results included a $181.7 million pre-tax loss on the CDMO and Cell Solutions divestiture, which the company recorded within Other expense, net. Cash flow from operations was $474.9 million, down from $590.1 million, mainly due to higher variable compensation payments. The company spent $467.3 million on acquisitions, including the Cambodian NHP Supplier and PathoQuest, and repurchased $300.0 million of stock, leaving $700.0 million available under its program. Total debt and finance leases rose to $2.46 billion, with the revolving facility balance at $943.2 million. Management announced the multi-year Create the Future restructuring program in September 2026, targeting more than $300 million of incremental annualized cost savings between 2027 and 2030. The filing also discloses an ongoing putative securities class action and two stayed derivative lawsuits, all tied to importation of non-human primates. The company states it believes these claims are without merit and cannot reasonably estimate potential exposure or loss.
- 2026-Q2Aug 5, 2026
Charles River Laboratories International Quarterly Report for Q2 Ended Jun 27, 2026
Charles River Laboratories International, Inc. reported second-quarter 2026 total revenue of $1,004.1 million, down $28.1 million, or 2.7%, from $1,032.1 million a year earlier. Revenue for the six months ended June 27, 2026 was $1,999.9 million, down 0.8% from $2,016.3 million. The decline reflected the sale of the CDMO business and the European Discovery Services divestiture, along with lower cell supply revenue. Operating income rose to $119.9 million, or 11.9% of revenue, from $100.1 million, or 9.7%, mainly because of a gain on the Wilmington, Massachusetts asset sale, lower accelerated amortization, and lower 2025 third-party legal costs. Net loss attributable to common shareholders was $1.5 million for the quarter, compared with net income of $52.3 million in the prior-year quarter. The result was driven by a $63.7 million loss on the CDMO and Cell Solutions divestiture. For the six months, the company reported a net loss attributable to common shareholders of $16.3 million, including a $181.7 million divestiture loss. Cash flow from operations was $220.8 million for the six months, compared with $376.3 million a year earlier. The company attributed the decline to higher variable compensation payments and acquisition, integration and divestiture-related payments. Investing activities included $467.3 million for acquisitions, primarily the Cambodian NHP supplier with a preliminary purchase price of $507.3 million, and PathoQuest, at $67.6 million. Total long-term debt, net and finance leases rose to $2.62 billion from $2.14 billion, with the revolving facility balance increasing to $1.12 billion from $616.5 million. The company repurchased $300.0 million of stock during the six months and had $700.0 million remaining under its repurchase authorization at June 27, 2026. Management stated that cumulative annualized cost savings of approximately $300 million are expected by the end of 2026, and that DSA backlog increased slightly to $2.0 billion from $1.9 billion. The filing also discloses a putative securities class action and two derivative lawsuits, which management believes are without merit. The company cannot reasonably estimate the potential exposure from these matters.
- 2026-Q1May 7, 2026
Charles River Laboratories International Quarterly Report for Q1 Ended Mar 28, 2026
Charles River Laboratories International, Inc. reported a first-quarter 2026 net loss attributable to common shareholders of $14.8 million ($0.30 per diluted share), compared with net income of $25.5 million ($0.50 per diluted share) in the prior-year quarter. The decline was driven principally by a $118.0 million pre-tax loss on assets held for sale tied to the CDMO and Cell Solutions Divestiture, which was completed on May 6, 2026. Total revenue rose $11.7 million, or 1.2%, to $995.8 million, led by Manufacturing (up 6.8%) and DSA (up 0.7%), partly offset by RMS (down 2.2%). Operating income increased 60.6% to $119.9 million, helped by a $38.5 million pre-tax gain on the sale of Wilmington, Massachusetts assets and the absence of prior-year accelerated amortization. Cash flow and balance sheet activity were significant. Operating cash flow fell to $41.1 million from $171.7 million, mainly due to higher annual incentive bonus payments. The company spent $405.0 million on acquisitions, primarily the Cambodian NHP Supplier, which closed January 14, 2026 for a preliminary purchase price of $507.3 million. Long-term debt, net rose to $2.66 billion from $2.14 billion, with the revolving facility balance increasing to $1.17 billion. The company repurchased $200.0 million of stock during the quarter and had $800.0 million remaining under its $1.0 billion authorization. Management stated that DSA backlog was consistent at $1.9 billion and that the client base remains cautious in spending, principally in DSA. The company also disclosed a cybersecurity incident involving unauthorized access to certain information systems, which it said had not had a material impact as of the filing date, and noted ongoing securities and derivative litigation related to non-human primate importation disclosures.
- 2025-Q3Nov 5, 2025
Charles River Laboratories International Quarterly Report for Q3 Ended Sep 27, 2025
Charles River Laboratories International, Inc. reported third-quarter 2025 revenue of $1,004.9 million, down 0.5% from $1,009.8 million a year earlier, and nine-month revenue of $3,021.2 million, down 0.9%. The filing attributes the declines mainly to lower volume in the DSA and Manufacturing segments, reflecting continued cautious client spending, partly offset by higher RMS revenue, which the filing ties primarily to Noveprim. Operating income rose to $133.8 million (13.3% of revenue) in the quarter from $117.4 million (11.6%), driven by lower severance costs and lower unallocated corporate compensation. For the nine months, operating income fell to $308.6 million (10.2% of revenue) from $395.0 million (13.0%), reflecting accelerated amortization of certain CDMO client relationships after the loss of key customers, higher restructuring and impairment charges, and higher third-party legal and advisory costs. Below the operating line, earnings were pressured by $21.1 million of net losses and impairments on venture capital and strategic equity investments in the quarter. Net income available to common shareholders was $54.4 million for the quarter (diluted EPS of $1.10, versus $1.33) and $132.2 million for the nine months (diluted EPS of $2.65, versus $4.37). The effective tax rate rose to 36.3% in the quarter from 23.0%. Nine-month operating cash flow was $590.1 million, up from $575.2 million. The company repurchased $350.0 million of stock during the nine months and, on October 29, 2025, approved a new $1.0 billion repurchase authorization. Management disclosed that DSA backlog declined to $1.8 billion from $2.0 billion, and that restructuring actions are expected to yield about $225 million of annualized cost savings. In November 2025, the Board announced outcomes of its strategic review, including divesting certain underperforming or non-core assets (about 7% of estimated 2025 revenue) and initiatives expected to generate about $70 million of incremental annual net cost savings, fully realized in 2026. The company also remains subject to an SEC inquiry and securities and derivative litigation related to its non-human primate sourcing, which it says it believes lack merit and plans to defend vigorously.
- 2025-Q2Aug 6, 2025
Charles River Laboratories International Quarterly Report for Q2 Ended Jun 28, 2025
Charles River Laboratories International, Inc. reported second-quarter 2025 results (three months ended June 28, 2025) with total revenue of $1,032.1 million, up 0.6% from $1,026.1 million a year earlier, while operating income fell to $100.1 million from $151.7 million, and net income attributable to the company's common shareholders decreased to $52.3 million from $90.0 million. For the six months, revenue declined 1.0% to $2,016.3 million and operating income dropped to $174.8 million from $277.6 million. The filing attributes the profit decline mainly to accelerated amortization of certain CDMO client relationships after loss of key customers, higher restructuring and asset impairment charges, and higher third-party legal and advisory costs. DSA revenue declined on cautious client spending, with DSA backlog at $1.9 billion versus $2.0 billion at December 28, 2024. Cash flow from operations improved to $376.3 million for the six months from $323.4 million, while the company repurchased $350.0 million of stock under its $1.0 billion program and had $549.3 million remaining authorization at quarter end. Total debt and finance leases rose to $2.35 billion, and the revolving facility balance increased to $813.0 million from $714.9 million. The company disclosed a Cooperation Agreement with Elliott Investment Management and a comprehensive strategic review overseen by the Board's Strategic Partnership and Capital Allocation Committee, with no assurance the review will produce a transaction. The filing also details ongoing exposure from the non-human primate supply chain matters. The DOJ grand jury and parallel civil investigations were closed, USFWS cleared the Cambodian NHP shipments for entry, and the SEC investigation, a securities class action on appeal, and two stayed derivative lawsuits remain pending, with the company unable to estimate potential losses. The company also cites restructuring actions expected to yield about $225 million in annualized cost savings, of which about $175 million affects fiscal 2025.
- 2025-Q1May 7, 2025
Charles River Laboratories International Quarterly Report for Q1 Ended Mar 29, 2025
Charles River Laboratories International, Inc. reported first-quarter 2025 results (three months ended March 29, 2025) with total revenue of $984.2 million, down $27.4 million, or 2.7%, from $1,011.6 million a year earlier. The decline was driven mainly by lower volume in the DSA segment, where clients continued to spend cautiously, with smaller declines in RMS and Manufacturing. Operating income fell to $74.7 million (7.6% of revenue) from $126.0 million (12.5%), reflecting lower revenue, $65.3 million of intangible amortization (including $35.5 million of accelerated amortization tied to lost key CDMO customers), restructuring charges of $23.8 million, and third-party legal costs in DSA. Net income attributable to the company's common shareholders declined to $25.5 million, or $0.50 per diluted share, from $67.3 million, or $1.30 per diluted share. Cash generation improved, with operating cash flow of $171.7 million versus $129.9 million, helped by lower variable compensation payments and favorable supplier payment timing. The company spent $350.0 million repurchasing 2.1 million shares under its $1.0 billion authorization, leaving $549.3 million available, and net revolving credit facility borrowings of $267.5 million raised total debt and finance leases to $2.53 billion. Cash and cash equivalents were $229.4 million at quarter-end, and the company reports that it believes existing funds and financing access are sufficient for the foreseeable future. The filing also flags ongoing risks: U.S. DOJ, USFWS, and SEC investigations into non-human primate sourcing, securities and derivative lawsuits, new tariffs affecting supply from Vietnam, Mauritius, and China, and reduced NIH funding and FDA moves to reduce animal testing. On May 6, 2025, the company entered a Cooperation Agreement with a large shareholder and agreed to a comprehensive strategic review overseen by the Strategic Partnership and Capital Allocation Committee.
- 2024-Q3Nov 6, 2024
Charles River Laboratories International Quarterly Report for Q3 Ended Sep 28, 2024
Charles River Laboratories International, Inc.'s Form 10-Q for the quarter ended September 28, 2024 shows total revenue of $1,009.8 million for the three months, down $16.9 million or 1.6% from $1,026.6 million a year earlier, and $3,047.4 million for the nine months, down $68.5 million or 2.2%. The decline was driven mainly by lower volume in the DSA segment, partly offset by growth in Manufacturing and the Noveprim acquisition. Operating income fell to $117.4 million (11.6% of revenue) for the quarter from $151.5 million, and to $395.0 million (13.0% of revenue) for the nine months from $484.3 million. The filing attributes the drop mainly to lower revenue and restructuring charges of $30.6 million in the quarter and $65.6 million year to date. Net income attributable to common shareholders was $68.7 million for the quarter (diluted EPS $1.33) and $226.0 million for the nine months (diluted EPS $4.37). Cash flow from operations improved to $575.2 million for the nine months, up from $463.0 million, while capital expenditures fell to $157.4 million from $240.2 million. Long-term debt, net and finance leases declined to $2.33 billion from $2.65 billion, mainly from net repayments on the revolving facility. The company repurchased 0.5 million shares for $100.7 million under a new $1.0 billion authorization approved August 2, 2024, leaving $899.3 million available. The filing also reports that the company is cooperating with U.S. DOJ, USFWS and SEC investigations into its non-human primate supply chain, and that a putative securities class action was dismissed in July 2024 and is on appeal. The company says it cannot estimate the potential exposure from these matters. In the DSA segment, the Discovery Services goodwill reporting unit's fair value exceeded its carrying value by approximately 22%, and no impairment was recognized.
- 2024-Q2Aug 7, 2024
Charles River Laboratories International Quarterly Report for Q2 Ended Jun 29, 2024
Charles River Laboratories International, Inc. reported a quarter ended June 29, 2024 with total revenue of $1,026.1 million, down from $1,059.9 million in the prior-year quarter, a decrease of $33.8 million or 3.2%. The filing attributes the decline primarily to lower volume in the DSA business, partially offset by higher Manufacturing revenue and the Noveprim acquisition. Operating income fell to $151.7 million (14.8% margin) from $164.9 million (15.6%), and net income available to common shareholders decreased to $90.0 million from $97.0 million. For the six months, revenue was $2,037.7 million, down 2.5%, and operating income was $277.6 million versus $332.8 million, with restructuring charges of $35.0 million in the period. Cash flow from operations improved to $323.4 million for the six months from $257.5 million, driven by working capital improvements. Cash and cash equivalents fell to $179.2 million, and long-term debt, net and finance leases declined to $2,409.4 million from $2,647.1 million as the revolving facility was paid down. DSA backlog decreased to $2.2 billion from $2.5 billion, and management cited a more cautious spending environment among biopharmaceutical clients. The company expects restructuring actions to yield more than $150 million in annualized cost savings, of which about $100 million affects fiscal 2024. The filing also details ongoing U.S. government investigations into non-human primate sourcing, a securities class action that was dismissed on July 1, 2024 and is now under appeal, and derivative lawsuits, with the company stating it cannot reasonably estimate potential exposure. On August 2, 2024, the Board approved a new $1.0 billion stock repurchase authorization replacing the prior program, which had $129.1 million remaining.
- 2024-Q1May 9, 2024
Charles River Laboratories International Quarterly Report for Q1 Ended Mar 30, 2024
Charles River Laboratories International, Inc. reported total revenue of $1,011.6 million for the three months ended March 30, 2024, down $17.8 million, or 1.7%, from $1,029.4 million in the prior-year quarter. The decline was driven mainly by lower volume in the DSA segment, partly offset by higher RMS revenue (including the Noveprim acquisition) and higher Manufacturing revenue. Operating income fell to $126.0 million, a 12.5% operating margin, versus $167.9 million and 16.3% a year earlier, reflecting lower revenue, higher staffing and operating costs, and restructuring charges of about $17 million. Net income available to common shareholders decreased to $73.0 million from $103.1 million, though diluted EPS as presented was $1.30 versus $2.01 after noncontrolling interest and dividend adjustments. Cash flow from operations improved to $129.9 million from $109.4 million, driven by timing of vendor payments and improvements in revenue-related accounts. Total debt and finance leases were $2.68 billion at quarter end, with cash and cash equivalents of $327.0 million. The company repurchased no shares under its $1.3 billion program during the quarter, leaving $129.1 million authorized, and management stated the company believes existing funds are sufficient for foreseeable operations. The filing also details ongoing U.S. government investigations by the DOJ, USFWS and SEC related to non-human primate shipments from Cambodia, a securities class action, and a derivative lawsuit. The company states it believes the concerns are without merit, cannot predict outcomes, and cannot reasonably estimate potential exposure for the class action or derivative suit. Inventory tied to the Cambodia-sourced shipments was approximately $27 million.
- 2023-Q3Nov 8, 2023
Charles River Laboratories International Quarterly Report for Q3 Ended Sep 30, 2023
Charles River Laboratories International, Inc. reported third-quarter 2023 total revenue of $1,026.6 million, up from $989.2 million in the prior-year quarter, an increase of 3.8%. Growth was driven mainly by higher volume and pricing in the Safety Assessment business, partially offset by the divestiture of the Avian Vaccine Services business. Operating income was essentially flat at $151.5 million, with operating margin falling to 14.8% from 15.3%, reflecting higher Manufacturing operating costs, restructuring and asset impairment charges, and the Avian divestiture. Net income attributable to common shareholders declined to $87.4 million from $96.5 million, mainly due to higher interest expense from higher rates on variable-rate debt. For the nine months ended September 30, 2023, total revenue was $3,115.9 million, up 8.3%, and net income attributable to common shareholders was $287.5 million versus $298.8 million a year earlier. Net cash provided by operating activities rose to $463.0 million from $384.9 million. The DSA backlog decreased to $2.60 billion from $3.15 billion at December 31, 2022, and management described a more cautious client spending environment, though it noted sequential improvement in the DSA net book-to-bill ratio and study cancellation rate in the third quarter. The filing also details ongoing U.S. government investigations by the DOJ, USFWS and SEC into the company's non-human primate supply chain, including shipments from Cambodia, and a putative securities class action filed May 19, 2023. The company states it believes the concerns and the class action are without merit, and it cannot predict the outcome or estimate potential exposure. The company also agreed to acquire an additional 41% equity stake in a DSA supplier for a preliminary price of $143 million in cash, with closing subject to regulatory approval.
- 2023-Q3Aug 9, 2023
Charles River Laboratories International Quarterly Report for Q3 Ended Jul 1, 2023
Charles River Laboratories International, Inc. reported second-quarter 2023 results in this Form 10-Q for the period ended July 1, 2023. Total revenue for the three months rose to $1,059.9 million from $973.1 million, an increase of 8.9%, driven mainly by Safety Assessment volume and pricing and the Explora BioLabs acquisition, partly offset by the Avian divestiture. Operating income fell to $164.9 million from $187.4 million, with operating margin of 15.6% versus 19.3%, mainly because of lower Manufacturing segment operating income, particularly in Biologics Solutions. Net income attributable to common shareholders was $97.0 million, or $1.89 per diluted share, compared with $109.3 million, or $2.13, a year earlier. Interest expense rose sharply to $35.0 million from $3.7 million, reflecting higher interest rates on variable-rate debt. Cash flow from operations for the six months was $257.5 million, versus $252.1 million a year earlier. The company's DSA backlog declined to $2.76 billion from $3.15 billion at December 31, 2022, and management described a more cautious spending environment from biopharmaceutical clients. Total debt and finance leases were $2.70 billion at July 1, 2023, and the company had $129.1 million remaining under its $1.3 billion stock repurchase program. In the first half, it did not repurchase shares under that program. The filing also details significant legal and regulatory exposure. The U.S. Department of Justice and U.S. Fish and Wildlife Service are investigating shipments of non-human primates from Cambodia, the company has voluntarily suspended such shipments, and the SEC has made an inquiry. A putative securities class action was filed on May 19, 2023. The company states it cannot predict the outcome or estimate the range of possible loss. It also agreed on July 28, 2023 to acquire an additional 41% stake in a DSA supplier for $143 million in cash, plus contingent payments of up to $55 million, subject to regulatory approval.
- 2023-Q2May 11, 2023
Charles River Laboratories International Quarterly Report for Q2 Ended Apr 1, 2023
Charles River Laboratories International, Inc. reported revenue of $1,029.4 million for the three months ended April 1, 2023, up 12.6% from $913.9 million a year earlier, driven mainly by increased demand and pricing in its Safety Assessment business and the Explora BioLabs acquisition, partially offset by the Avian divestiture and currency effects. Operating income rose to $167.9 million from $148.8 million, with the operating margin flat at 16.3%. Net income attributable to common shareholders was $103.1 million, or $2.01 per diluted share, compared with $93.0 million, or $1.81 per diluted share, a year earlier. Interest expense more than doubled to $34.4 million from $9.4 million, reflecting higher interest rates, and the effective tax rate rose to 20.7% from 14.1%. Segment results were uneven. DSA revenue grew 21.7% to $662.4 million with operating income up 63.3%, while Manufacturing operating income fell to $2.1 million from $46.4 million on higher costs in Biologics Solutions and the Avian divestiture. RMS operating income declined 15.6% to $40.4 million, mainly due to timing of large research model sales in China and costs tied to Explora BioLabs. Cash provided by operations was $109.4 million, while capital expenditures were $106.9 million. The company made no share repurchases in the quarter and had $129.1 million remaining under its $1.3 billion authorization. Total debt and finance leases were $2.77 billion as of April 1, 2023. The filing also discloses that the U.S. Department of Justice and U.S. Fish and Wildlife Service are investigating the company's shipments of non-human primates from Cambodia, which has prompted a grand jury subpoena and a voluntary suspension of future shipments from that country. The company says it is cooperating and believes the concerns are without merit, but it cannot predict the timing, outcome, or possible impact, including potential fines, penalties or liabilities.
- 2022-Q3Nov 2, 2022
Charles River Laboratories International Quarterly Report for Q3 Ended Sep 24, 2022
Charles River Laboratories International, Inc. reported third-quarter 2022 total revenue of $989.2 million, up 10.4% from $895.9 million a year earlier, and nine-month revenue of $2.9 billion, up 9.1%. Growth was driven mainly by higher demand and pricing in the DSA segment and the Explora BioLabs acquisition, partially offset by the divestitures of RMS Japan and CDMO Sweden and unfavorable foreign currency effects. Operating income for the quarter was $151.0 million (15.3% margin) versus $155.8 million (17.4%) a year earlier, reflecting higher CDMO operating costs, staffing costs and inflationary pressures. Net income attributable to common shareholders was $96.5 million for the quarter, down from $103.4 million, while nine-month net income rose to $298.8 million from $253.4 million. Cash flow from operations for the nine months was $384.9 million, compared with $531.5 million a year earlier, driven by working capital timing. Capital expenditures rose to $235.7 million, and total debt and finance leases were $2.96 billion, with the revolving facility at $1.43 billion. The company had $129.1 million remaining under its stock repurchase program and did not repurchase shares under it during the nine months. Subsequent to the quarter, on November 1, 2022, the company agreed to sell its Avian Vaccine Services business for approximately $170 million in cash plus up to an additional $30 million in contingent payments, with closing expected in the fourth quarter of fiscal 2022. The company also entered into a $500 million interest rate swap in early November 2022 to fix the rate on floating-rate Credit Facility borrowings.
- 2022-Q2Aug 3, 2022
Charles River Laboratories International Quarterly Report for Q2 Ended Jun 25, 2022
Charles River Laboratories International, Inc. reported second-quarter 2022 results (three months ended June 25, 2022) with total revenue of $973.1 million, up from $914.6 million a year earlier, and net income attributable to common shareholders of $109.3 million, compared with $88.4 million. Diluted EPS was $2.13 versus $1.72. Growth was driven mainly by demand in the DSA and RMS segments, partly offset by the RMS Japan and CDMO Sweden divestitures and foreign currency effects. Operating income rose to $187.4 million (19.3% of revenue) from $137.6 million, aided by lower acquisition costs, a favorable contingent consideration adjustment, and a favorable indirect tax ruling. For the six months, revenue was $1,887.1 million, up from $1,739.2 million, and net income attributable to common shareholders was $202.3 million, up from $150.0 million. Operating cash flow fell to $252.1 million from $356.8 million, reflecting working capital timing, while capital expenditures rose to $163.3 million from $74.5 million. Total debt and finance leases were $3.02 billion at June 25, 2022, up from $2.69 billion, mainly from revolver borrowings used to fund the $284.5 million Explora BioLabs acquisition. Cash and cash equivalents were $200.3 million. Net investment losses weighed on other expense, which was $39.8 million in the quarter, including venture capital and life insurance investment losses and foreign currency losses on a U.S. dollar loan. The company completed $129.1 million remaining on its stock repurchase authorization but did not repurchase shares under the program during the six months and stated it does not intend to repurchase shares for the remainder of 2022.
- 2022-Q1May 4, 2022
Charles River Laboratories International Quarterly Report for Q1 Ended Mar 26, 2022
Charles River Laboratories International, Inc. reported first-quarter 2022 total revenue of $913.9 million, up from $824.6 million in the prior-year quarter, a 10.8% increase. The increase was driven mainly by the DSA segment and recent acquisitions, principally in Manufacturing, partially offset by the divestiture of RMS Japan and unfavorable foreign currency effects. Operating income rose to $148.8 million (16.3% operating margin) from $123.7 million (15.0%), and net income attributable to common shareholders increased to $93.0 million from $61.5 million, helped by the absence of the prior-year debt extinguishment costs tied to the 2026 Senior Notes repayment. Diluted EPS was $1.81 versus $1.20. Cash flow from operations declined to $102.6 million from $170.2 million, reflecting working capital timing, mainly variable compensation payments and customer contract collections. Capital expenditures rose to $80.5 million from $28.0 million. Total debt and finance leases were $2.70 billion at March 26, 2022, with a weighted average interest rate of 2.87%, and cash and cash equivalents were $241.9 million. Subsequent to the quarter, the company acquired Explora BioLabs for approximately $295 million in cash, funded through its Credit Facility, and acquired a 49% equity interest in a DSA supplier for approximately $90 million upfront. The company did not repurchase shares under its program during the quarter and remains with $129.1 million authorized, and it does not intend to repurchase shares for the remainder of 2022.
- 2021-Q3Nov 3, 2021
Charles River Laboratories International Quarterly Report for Q3 Ended Sep 25, 2021
Charles River Laboratories International, Inc. reported third-quarter 2021 revenue of $895.9 million, up from $743.3 million in the prior-year quarter, and net income attributable to common shareholders of $103.4 million, compared with $102.9 million a year earlier. Diluted EPS was $2.01 versus $2.03. For the nine months, total revenue rose to $2.64 billion from $2.13 billion, and net income attributable to common shareholders reached $253.4 million versus $221.1 million. Operating income for the nine months was $417.1 million, compared with $303.8 million in the prior-year period. The filing attributes the revenue growth mainly to demand across all segments, principally in DSA, the recovery of RMS from COVID-19 disruptions in the prior-year period, and recent acquisitions, mostly in Manufacturing. The company made significant acquisitions during 2021, including Cognate BioServices for a preliminary purchase price of $876.1 million, Vigene Biosciences for $326.1 million, Retrogenix, Distributed Bio, and certain distributor assets. Cash paid for acquisitions of businesses and assets, net of cash acquired, totaled $1.29 billion for the nine months. Goodwill increased to $2.74 billion from $1.81 billion at fiscal year-end 2020, and total debt and finance leases reached $2.92 billion. To fund this, the company issued $1.0 billion of 3.75% Senior Notes due 2029 and 4.00% Senior Notes due 2031, and amended its Credit Facility to a $3.0 billion multi-currency revolving facility maturing in April 2026. Operating cash flow for the nine months was $531.5 million, versus $408.2 million a year earlier. After the quarter end, on October 12, 2021, the company completed the sale of its RMS Japan operations to The Jackson Laboratory for approximately $63 million in cash and the sale of its gene therapy CDMO site in Sweden for approximately $52 million in cash, with potential contingent payments of up to an additional $25 million. The company also disclosed no share repurchases during the nine months and $129.1 million remaining under its repurchase authorization. The filing notes the company is a federal contractor subject to a U.S. employee COVID-19 vaccination requirement effective December 8, 2021.
- 2021-Q2Aug 4, 2021
Charles River Laboratories International Quarterly Report for Q2 Ended Jun 26, 2021
Charles River Laboratories International, Inc. reported a strong second quarter of 2021 for the three months ended June 26, 2021. Total revenue rose to $914.6 million from $682.6 million, and operating income increased to $137.5 million from $76.8 million. Net income attributable to common shareholders was $88.4 million, or $1.72 per diluted share, compared with $67.4 million, or $1.34 per diluted share, a year earlier. For the six months, total revenue was $1.74 billion and net income attributable to common shareholders was $150.0 million, or $2.93 per diluted share. The filing attributes the growth to increased demand across all three segments, principally in DSA, the recovery of RMS from COVID-19 disruptions in the prior-year period, and contributions from acquisitions, mainly in Manufacturing. The company made substantial acquisitions in the period, most notably Cognate BioServices with a preliminary purchase price of $876.1 million net of cash acquired, and Vigene Biosciences for a preliminary $292.5 million in cash, which closed on June 28, 2021. Acquisitions of businesses and assets, net of cash acquired, totaled $1.00 billion for the six months. To fund these deals, the company issued $1.0 billion of 3.75% Senior Notes due 2029 and 4.00% Senior Notes due 2031, repaid its 5.5% Senior Notes due 2026, and amended its Credit Facility to a $3.0 billion multi-currency revolving facility maturing in April 2026. Total debt rose to $2.75 billion at June 26, 2021, from $1.99 billion at December 26, 2020. Operating cash flow was $356.8 million for the six months, up from $230.9 million. Management stated it did not repurchase shares under the authorized program during the six months and does not intend to repurchase shares for the remainder of 2021, leaving $129.1 million available under the authorization. The company also reported increased interest rate exposure, noting that a 100-basis-point rise in rates would increase annual pre-tax interest expense by $12.3 million, and it disclosed new risk factors related to its CDMO business.
- 2021-Q1May 4, 2021
Charles River Laboratories International Quarterly Report for Q1 Ended Mar 27, 2021
Charles River Laboratories International, Inc. reported first-quarter 2021 results for the three months ended March 27, 2021. Total revenue rose to $824.6 million from $707.1 million, and the filing states the increase of $117.5 million, or 16.6%, was driven mainly by increased demand across all segments, principally DSA, plus a $21.1 million favorable foreign currency effect. Operating income increased to $123.7 million (15.0% of revenue) from $94.3 million (13.3%). Net income attributable to common shareholders rose to $61.5 million from $50.8 million, though results were partly offset by $26 million of debt extinguishment costs tied to the repayment of the 2026 Senior Notes. Diluted EPS was $1.20 versus $1.02 in the prior-year quarter. The company significantly expanded its balance sheet and debt structure during the quarter. It issued $1 billion of unregistered senior notes (3.75% due 2029 and 4.00% due 2031), used proceeds to repay the 5.5% 2026 Senior Notes and the remaining $146.9 million term loan, and paid for a portion of the Cognate BioServices acquisition, a cell and gene therapy CDMO acquired March 29, 2021 for approximately $875 million in cash. Total debt and finance leases were $2.22 billion at quarter-end, up from $1.99 billion at year-end, and cash and cash equivalents rose to $465.4 million. Operating cash flow was $170.2 million versus $68.6 million a year earlier. The company also bought back no shares under its repurchase program, with $129.1 million remaining, and stated in the filing that it does not intend to repurchase shares for the remainder of 2021. Subsequent to quarter-end, in April 2021, the Credit Facility was amended and restated to create a $3.0 billion multi-currency revolving facility maturing in April 2026. The filing also notes the company's operations were affected by COVID-19, although it states there were no material changes to its assessment of the pandemic during the quarter, and that DSA and Manufacturing revenue were not significantly impacted by it.
- 2020-Q3Oct 29, 2020
Charles River Laboratories International Quarterly Report for Q3 Ended Sep 26, 2020
Charles River Laboratories International, Inc. reported third-quarter 2020 total revenue of $743.3 million, up from $667.95 million in the prior-year quarter, and net income attributable to common shareholders of $102.9 million, compared with $72.8 million a year earlier. Diluted EPS was $2.03 versus $1.46. Operating income rose to $132.8 million from $92.8 million, with the DSA and Manufacturing segments driving most of the improvement. RMS operating income was $37.1 million versus $34.4 million, but RMS operating margin fell as acquisition-related amortization increased. For the nine months, revenue was $2.13 billion and net income attributable to common shareholders was $221.1 million, against $171.7 million a year earlier. The filing attributes the RMS slowdown in the first half to COVID-19 closures of client facilities, with demand recovering in the third quarter. Balance sheet and cash flow changes were driven by acquisitions. The company acquired HemaCare for $379.8 million in cash in January 2020 and Cellero for $37.5 million in August 2020. Total debt and finance leases were $2.0 billion at September 26, 2020, and the company had $1.2 billion available on its revolver. Operating cash flow for the nine months was $408.2 million, up from $300.3 million. Management stated it does not currently anticipate needing to borrow additional funds during 2020, and that it did not identify a going-concern uncertainty. The filing also discloses that the U.S. Pension Plan was settled in October 2020, with an expected non-cash settlement charge of approximately $10 million. The company disclosed that it had $129.1 million remaining under its stock repurchase program and did not repurchase shares in the quarter. A cybersecurity incident detected in March 2019 is discussed in the risk factors, and the company said remediation was completed in December 2019.
- 2020-Q2Aug 5, 2020
Charles River Laboratories International Quarterly Report for Q2 Ended Jun 27, 2020
Charles River Laboratories International, Inc. reported total revenue of $682.6 million for the three months ended June 27, 2020, up from $657.6 million a year earlier, an increase the filing describes as 3.8%. Growth came mainly from the Citoxlab and HemaCare acquisitions and from the DSA and Manufacturing segments, partly offset by COVID-19-related declines in RMS research model product revenue. Operating income fell to $76.8 million from $79.8 million, and operating margin was 11.2% versus 12.1%. Net income attributable to common shareholders rose to $67.4 million from $43.7 million, mainly because of venture capital and life insurance policy gains, not operations. Diluted earnings per share were $1.34 compared with $0.88. For the six months ended June 27, 2020, revenue was $1.39 billion, up 10.1%, and operating income was $171.0 million, a 12.3% margin. Operating cash flow was $230.9 million versus $144.4 million, helped by higher net income and working capital timing. The RMS segment was the main weak spot: quarterly revenue fell 14.3% to $116.5 million and operating income fell to $3.8 million from $31.5 million, as clients' academic facilities closed. DSA revenue grew 9.1% to $442.6 million, and Manufacturing revenue grew 6.4% to $123.5 million. At June 27, 2020, the company had cash and cash equivalents of $402.0 million and total debt and finance leases of $2.3 billion. Management stated that it had drawn an extra $150 million on its revolver in the first quarter as a COVID-19 precaution and does not expect to need additional borrowings in 2020. The company reported that it was compliant with all debt covenants and that there was no significant uncertainty about its ability to continue as a going concern. It made no share repurchases in the six months and does not intend to repurchase shares for the rest of 2020. A definitive agreement to acquire Cellero, LLC for approximately $38 million in cash was signed on August 4, 2020, with closing expected in August 2020.
- 2020-Q1May 7, 2020
Charles River Laboratories International Quarterly Report for Q1 Ended Mar 28, 2020
Charles River Laboratories International, Inc. reported first-quarter 2020 total revenue of $707.1 million, up from $604.6 million in the prior-year quarter, an increase the company attributes primarily to the recent acquisitions of Citoxlab and HemaCare along with growth in its DSA and Manufacturing segments, partly offset by lower RMS product revenue from COVID-19. Operating income rose to $94.3 million (13.3% of revenue) from $69.8 million (11.5%), but net income attributable to common shareholders declined to $50.8 million from $55.1 million, driven by net losses on venture capital and life insurance policy investments versus gains a year earlier. Diluted EPS was $1.02 compared with $1.11. The balance sheet expanded materially with acquisitions. Goodwill rose to $1.73 billion and total debt and finance leases reached $2.39 billion at March 28, 2020, versus $1.91 billion at December 28, 2019, after the company borrowed $150 million extra on its revolver as a precaution against COVID-19 liquidity risk. Operating cash flow improved to $68.6 million from $14.9 million, and cash and cash equivalents ended the quarter at $372.4 million. The company made no share repurchases in the quarter and states it does not intend to repurchase shares for the remainder of 2020. Management expects reduced demand for research models in RMS to continue, a small-to-modest adverse impact on DSA, and a minor-to-small adverse impact on Manufacturing through the rest of the year. The company states it does not believe there is significant uncertainty in its ability to continue as a going concern, and it does not anticipate needing to draw additional borrowings in 2020.
- 2019-Q3Nov 6, 2019
Charles River Laboratories International Quarterly Report for Q3 Ended Sep 28, 2019
Charles River Laboratories International, Inc. reported third-quarter 2019 results with total revenue of $667.95 million for the three months ended September 28, 2019, up from $585.30 million a year earlier, an increase the filing states as 14.1%. Growth was driven primarily by the Citoxlab acquisition and by growth in the DSA and Manufacturing segments, partially offset by unfavorable foreign currency effects of $7.7 million. Operating income was $92.80 million (13.9% of revenue) versus $84.36 million (14.4%) a year earlier. Net income attributable to common shareholders rose to $72.81 million, or $1.46 diluted EPS, helped by a $20.4 million deferred tax asset recognized in the quarter for expected future net operating losses, which produced a tax benefit for the quarter. For the nine months ended September 28, 2019, revenue was $1.93 billion, up 16.0% from $1.66 billion, with operating income of $242.36 million and net income attributable to common shareholders of $171.67 million. Cash flow from operations was $300.26 million, roughly flat year over year, while total debt and finance leases rose to $1.93 billion from $1.68 billion at year-end 2018, largely to fund acquisitions including Citoxlab ($527.7 million in cash). The filing also discloses an unauthorized access into the company's information systems detected in March 2019, in which some client data was copied; the company has not yet determined the potential revenue or financial impact. Subsequent to quarter end, the company issued $500.0 million of 4.25% Senior Notes due 2028 on October 23, 2019, used the proceeds with available cash to prepay $500.0 million of its term loan, and on November 4, 2019 increased its multi-currency revolving facility from $1.55 billion to $2.05 billion.
- 2019-Q2Jul 31, 2019
Charles River Laboratories International Quarterly Report for Q2 Ended Jun 29, 2019
Charles River Laboratories International, Inc. reported total revenue of $657.6 million for the three months ended June 29, 2019, up from $585.3 million a year earlier, an increase of $72.3 million, or 12.3%. The growth was primarily attributed to the recent acquisition of Citoxlab and to growth in the DSA and Manufacturing segments, partially offset by a $11.0 million (1.9%) negative foreign currency effect. Operating income was $79.8 million (12.1% of revenue) versus $76.7 million (13.1%) in the prior-year quarter, while net income attributable to common shareholders fell to $43.7 million from $53.7 million, mainly due to lower net gains on venture capital investments. For the six months, revenue rose to $1.26 billion from $1.08 billion, and net cash provided by operating activities declined to $144.4 million from $183.9 million. The balance sheet shows total assets of $4.63 billion and total debt and finance leases of $2.09 billion, compared with $1.68 billion at December 29, 2018, reflecting borrowings to fund the $528.1 million cash purchase of Citoxlab completed April 29, 2019. The company did not repurchase shares under its program during the six months and had $129.1 million remaining authorization. The filing states the company was compliant with all credit facility covenants as of June 29, 2019. The filing also discloses an unauthorized access into portions of the company's information systems detected in March 2019, in which some client data was copied. The company stated it had not yet determined the potential revenue or financial impact of the incident and that the investigation and remediation were ongoing.
- 2019-Q1May 7, 2019
Charles River Laboratories International Quarterly Report for Q1 Ended Mar 30, 2019
Charles River Laboratories International, Inc. reported first-quarter 2019 total revenue of $604.6 million, up from $494.0 million in the prior-year period, an increase of $110.6 million, or 22.4%. The filing attributes the growth primarily to the April 2018 acquisition of MPI Research and to growth in the DSA and Manufacturing segments, partially offset by an unfavorable foreign currency effect of $13.9 million, or 2.8%. Operating income rose to $69.8 million from $67.8 million, but operating margin declined to 11.5% from 13.7%, as the company cited increased amortization, acquisition-related costs, and investments in personnel and facilities. Net income attributable to common shareholders increased to $55.1 million, and diluted EPS was $1.11 versus $1.08. Cash generation weakened. Net cash provided by operating activities was $14.9 million, compared with $60.1 million in the prior-year period, which the company attributed mainly to unfavorable changes in operating assets and liabilities, including contract balances and accrued compensation. Total debt and finance leases were $1.59 billion at March 30, 2019, and cash and cash equivalents were $126.3 million. The company made no share repurchases under its program during the quarter, leaving $129.1 million authorized. Subsequent to quarter-end, on April 29, 2019, it acquired Citoxlab for €448 million in cash (about $500 million), funded with cash on hand and borrowings under its $2.3B Credit Facility. The filing also discloses an unauthorized access into portions of the company's information systems detected in March 2019, in which some client data was copied. The company has not yet determined the potential revenue or financial impact, and the investigation is ongoing.
- 2018-Q3Nov 7, 2018
Charles River Laboratories International Quarterly Report for Q3 Ended Sep 29, 2018
Charles River Laboratories International, Inc. reported revenue of $585.3 million for the three months ended September 29, 2018, up from $464.2 million a year earlier, an increase of $121.1 million or 26.1%. The filing attributes the increase primarily to the acquisitions of MPI Research, KWS BioTest and Brains On-Line, plus growth in the DSA and Manufacturing segments. For the nine months, revenue was $1.66 billion versus $1.38 billion, up 20.7%. Net income attributable to common shareholders was $60.4 million for the quarter ($1.22 diluted EPS) and $166.7 million for the nine months ($3.39 diluted EPS). Operating income for the quarter was $84.4 million, compared with $74.1 million, and operating margin declined to 14.4% from 16.0%, which the filing attributes to acquisition-related amortization and costs and continued investment in personnel, facilities and IT. The balance sheet and financing changed substantially during the period. Goodwill rose to $1.25 billion from $804.9 million, and total debt increased to $1.67 billion from $1.12 billion, following the April 2018 MPI Research acquisition for $829.7 million in cash. That acquisition was funded through a $2.3 billion credit facility and $500.0 million of 5.5% Senior Notes due 2026. Interest expense for the quarter rose to $17.2 million from $7.7 million. Nine-month operating cash flow was $301.2 million, compared with $193.8 million a year earlier, and cash and cash equivalents were $138.9 million at September 29, 2018. The company did not repurchase shares under its stock repurchase program during the nine months, leaving $129.1 million authorized. The filing also notes a Maryland research model facility being repurposed, restructuring charges that were modest in the period, and an effective tax rate of 16.9% for the quarter, reflecting U.S. Tax Reform benefits.
- 2018-Q2Aug 8, 2018
Charles River Laboratories International Quarterly Report for Q2 Ended Jun 30, 2018
Charles River Laboratories International, Inc. reported second-quarter 2018 total revenue of $585.3 million, up from $469.1 million a year earlier, with the filing attributing the increase primarily to the recent acquisitions of MPI Research, Brains On-Line and KWS BioTest along with growth in the DSA and Manufacturing segments. Service revenue rose to $438.5 million from $329.4 million. Operating income fell to $76.7 million from $81.7 million, as amortization of intangible assets, acquisition-related costs and continued investments in personnel, facilities and IT outweighed contributions from the acquired businesses. Net income attributable to common shareholders was $53.7 million, compared with $54.0 million in the prior-year quarter, supported by $12.0 million of other income, net, largely venture capital gains, and by U.S. Tax Reform benefits that lowered the effective tax rate to 24.8% from 28.9%. Diluted EPS for the quarter was $1.10, compared with $1.12 a year earlier. The balance sheet changed materially in the first half of 2018 due to the April 3, 2018 acquisition of MPI Research for $829.7 million in cash. Goodwill rose to $1.25 billion from $804.9 million, and long-term debt, net, increased to $1.77 billion from $1.09 billion. Funding came from a $2.3 billion credit facility, consisting of a $750.0 million term loan and a $1.55 billion revolving facility, plus $500.0 million of 5.5% Senior Notes due 2026. The company stated it was in compliance with all covenants as of June 30, 2018. Operating cash flow for the six months was $183.9 million, versus $134.4 million a year earlier, and no shares were repurchased under the stock repurchase program during the first half, leaving $129.1 million authorized. For the six months ended June 30, 2018, total revenue was $1.08 billion, up 18.0%, and net income attributable to common shareholders was $106.3 million, compared with $100.7 million. Management stated it believes existing funds, operating cash flow and financing access are sufficient to fund operations for the foreseeable future. The filing also notes that the company expects to recognize substantially all leases on the balance sheet upon adopting ASU 2016-02, and that it is still evaluating the impact of several new accounting standards.
- 2018-Q1May 10, 2018
Charles River Laboratories International Quarterly Report for Q1 Ended Mar 31, 2018
Charles River Laboratories International, Inc. reported first-quarter 2018 total revenue of $494.0 million, up from $445.8 million in the prior-year period, an increase of $48.2 million, or 10.8%, driven mainly by growth in the DSA and Manufacturing segments. Operating income was $67.8 million with an operating margin of 13.7%, compared with $69.7 million and 15.6% a year earlier, which the company attributed primarily to continued investments to support future growth. Net income attributable to common shareholders rose to $52.6 million from $46.8 million, helped by a $21.3 million reduction in the provision for income taxes, largely because the prior-year quarter included tax on the $18.0 million CDMO divestiture gain. Diluted EPS was $1.08 versus $0.97. The balance sheet and capital structure changed significantly. On March 26, 2018, the company amended its credit facility into a $2.3 billion facility with a $750.0 million term loan and a $1.55 billion multi-currency revolver. Total debt stood at $1.11 billion at quarter-end, and the company paid off a $601.3 million term loan. Subsequent to quarter-end, on April 3, 2018, the company acquired MPI Research for approximately $800 million in cash, funded by a $750.0 million term loan draw and the issuance of $500.0 million of 5.5% Senior Notes due 2026, with net proceeds of $493.8 million used to repay the revolver. Cash flow from operations improved to $60.1 million from $34.0 million, primarily on higher income and favorable working capital timing. Capital expenditures were $27.7 million, and the company did not repurchase any shares under its stock repurchase program during the quarter, leaving $115.5 million remaining under the $1.3 billion authorization. Management stated that existing funds, combined with operating cash flow and financing access, are sufficient for operations for the foreseeable future.
- 2017-Q3Nov 9, 2017
Charles River Laboratories International Quarterly Report for Q3 Ended Sep 30, 2017
Charles River Laboratories International, Inc. reported total revenue of $464.2 million for the three months ended September 30, 2017, up from $425.7 million in the prior-year quarter, a 9.0% increase. The company attributed the growth primarily to its DSA and Manufacturing segments. DSA revenue rose 14.4% to $246.9 million, and Manufacturing revenue rose 7.1% to $95.3 million, while RMS revenue increased 0.9% to $122.0 million. Operating income climbed to $74.0 million from $58.8 million, with operating margin of 15.9% versus 13.8%. Net income attributable to common shareholders was $52.5 million, or $1.08 per diluted share, compared with $37.7 million, or $0.79 per diluted share, a year earlier. For the nine months ended September 30, 2017, total revenue was $1,379.1 million, up 13.5%, and net income attributable to common shareholders was $153.2 million. Results benefited from the WIL Research acquisition, the Agilux and Brains On-Line acquisitions, and a $10.6 million gain on the February 2017 divestiture of the CDMO business, which sold for $75.0 million in proceeds. Net cash provided by operating activities was $193.8 million, compared with $198.3 million in the prior-year period. The company repurchased 1.0 million shares for $90.6 million during the nine months, and $129.1 million remained under its repurchase authorization at quarter end. Balance sheet and financing items include cash and cash equivalents of $123.6 million, $1,154.8 million outstanding under the $1.65B Credit Facility, and a weighted average interest rate on debt of 2.26%. The company stated it was compliant with all covenants as of September 30, 2017. In November 2017, the company committed to close its RMS production facility in Maryland by the end of 2018, with expected costs of $18 million to $24 million, the majority of which are non-cash and expected in the fourth quarter of 2017.
- 2017-Q3Aug 9, 2017
Charles River Laboratories International Quarterly Report for Q3 Ended Jul 1, 2017
Charles River Laboratories International, Inc. reported total revenue of $469.1 million for the three months ended July 1, 2017, up from $434.1 million in the prior-year quarter, with service revenue of $329.4 million and product revenue of $139.7 million. Net income attributable to common shareholders rose to $54.0 million, or $1.12 per diluted share, compared with $35.2 million, or $0.73 per diluted share, a year earlier. Operating income was $81.3 million versus $58.1 million. For the six months ended July 1, 2017, total revenue was $914.9 million and net income attributable to common shareholders was $100.7 million, or $2.08 per diluted share. The DSA segment drove growth, with revenue of $252.1 million in the quarter, up from $221.1 million, aided by the Agilux acquisition. The company divested its CDMO business to Quotient Clinical Ltd. on February 10, 2017 for $75.0 million in net proceeds and recorded a $10.6 million gain on the sale, which lifted other income in the first half. Income tax expense for the six months was $53.3 million, with an effective tax rate of 34.4%, reflecting tax on the divestiture gain partly offset by an $8.8 million excess tax benefit from stock compensation under ASU 2016-09. The company acquired Brains On-Line on August 4, 2017 for a preliminary purchase price of approximately €18 million in cash, plus potential additional payments of up to €6.7 million. Balance sheet and cash flow metrics were stable. Total debt was $1.12 billion as of July 1, 2017, down from $1.21 billion at December 31, 2016, and the company repaid $249.97 million of debt and related obligations in the period. Net cash provided by operating activities was $134.4 million for the six months, and the company repurchased $54.6 million of stock under its program, leaving $165.1 million of authorization remaining after the board increased it by $150 million to $1.3 billion in May 2017. The company stated it was compliant with all covenants under its $1.65 billion credit facility.
- 2017-Q2May 10, 2017
Charles River Laboratories International Quarterly Report for Q2 Ended Apr 1, 2017
Charles River Laboratories International, Inc. reported revenue of $445.8 million for the three months ended April 1, 2017, up from $354.9 million in the prior-year quarter, an increase of $90.9 million or 25.6% that the filing attributes largely to the WIL Research acquisition and Agilux. Net income attributable to common shareholders rose to $46.8 million ($0.97 diluted EPS) from $37.1 million ($0.78 diluted EPS). Results were helped by a $10.6 million gain on the February 2017 divestiture of the CDMO business, which sold for $75.0 million in proceeds, and by a $7.5 million excess tax benefit from the adoption of ASU 2016-09. The effective tax rate rose to 39.8% from 27.1%, mainly because of the tax on the divestiture gain. Segment results show DSA revenue of $227.8 million, up $69.8 million (44.2%), driven by the WIL Research safety assessment business, which contributed $57.5 million of growth. RMS revenue was $127.2 million and Manufacturing revenue was $90.8 million. Operating income rose to $69.5 million from $51.5 million, and amortization of intangible assets increased to $10.7 million from $6.4 million. Balance sheet and cash flow measures show total debt of $1.17 billion as of April 1, 2017, a weighted average interest rate of 2.07%, and cash and cash equivalents of $131.5 million. Net cash from operating activities was $34.0 million, down from $45.8 million, mainly due to a negative change in operating assets and liabilities. The company repurchased 0.4 million shares for $32.1 million and, after quarter-end on May 9, 2017, increased its repurchase authorization by $150.0 million to $1.3 billion.
- 2016-Q3Nov 2, 2016
Charles River Laboratories International Quarterly Report for Q3 Ended Sep 24, 2016
Charles River Laboratories International, Inc. filed this Form 10-Q for the quarter ended September 24, 2016. Total revenue for the three months rose to $425.7 million from $349.5 million, and for the nine months to $1.21 billion from $1.01 billion. Growth was driven largely by the WIL Research acquisition (completed April 4, 2016), which contributed $53.6 million to three-month revenue growth in the Safety Assessment business. Net income attributable to common shareholders was $37.7 million for the quarter versus $37.4 million a year earlier, and diluted EPS was $0.79 versus $0.79. Nine-month diluted EPS was $2.30 versus $2.47, reflecting higher interest expense and a higher effective tax rate of 30.4% compared with 18.3% in the prior-year period. The balance sheet expanded materially with acquisitions. Total assets rose to $2.69 billion from $2.07 billion at year-end 2015, goodwill increased to $763.6 million from $438.8 million, and long-term debt, net rose to $1.21 billion from $814.2 million. Net cash provided by operating activities was $186.1 million for the nine months, roughly flat year over year, while acquisitions used $597.6 million in cash. Cash and cash equivalents ended at $105.7 million. The company also disclosed a pending IDEXX patent infringement lawsuit, for which it stated an estimate of possible loss cannot be made, and a Brexit-related risk factor addition citing its substantial business in the E.U. and U.K. Subsequent to quarter end, the company acquired Agilux Laboratories for a preliminary purchase price of approximately $64.0 million in cash.
- 2016-Q2Aug 3, 2016
Charles River Laboratories International Quarterly Report for Q2 Ended Jun 25, 2016
Charles River Laboratories International, Inc. reported second-quarter 2016 total revenue of $434.1 million, up from $339.6 million in the prior-year quarter, with service revenue of $292.9 million and product revenue of $141.2 million. Operating income rose to $58.1 million from $55.7 million, but net income attributable to common shareholders fell to $35.2 million from $48.5 million, and diluted EPS from continuing operations was $0.73 versus $1.02. The decline was driven largely by higher interest expense of $8.9 million, a higher tax provision of $18.8 million, a smaller other income line, and SG&A of $100.5 million, which included $8.4 million of WIL Research transaction and integration costs. The quarter was shaped by acquisitions. WIL Research was acquired on April 4, 2016 for approximately $604.8 million, and Blue Stream Laboratories was acquired on June 27, 2016 for approximately $9.2 million in cash plus up to $3.0 million in contingent consideration. Funding came from cash on hand and borrowings under an amended credit facility, which was upsized to $1.65 billion on March 30, 2016. Total debt rose to $1,343.1 million at June 25, 2016 from $836.2 million at December 26, 2015. Goodwill increased to $754.9 million from $438.8 million, and total assets reached $2.76 billion. Cash flow from operations for the six months was $116.5 million, compared with $97.6 million a year earlier. Capital expenditures were $20.0 million. The filing also discloses a pending IDEXX patent infringement suit, for which the company stated it cannot estimate a loss range, a liability of about $1.5 million for excess government contract billings, and Brexit-related risk to its substantial E.U. and U.K. business.
- 2016-Q1May 4, 2016
Charles River Laboratories International Quarterly Report for Q1 Ended Mar 26, 2016
Charles River Laboratories International, Inc. reported first-quarter 2016 results (three months ended March 26, 2016) with total revenue of $354.9 million, up from $320.4 million in the prior-year quarter. Service revenue rose to $220.7 million and product revenue to $134.2 million. Operating income increased to $51.5 million from $43.0 million, and net income attributable to common shareholders was $37.1 million, or $0.78 per diluted share, compared with $31.5 million, or $0.66 per diluted share, a year earlier. The filing attributes revenue growth to higher Safety Assessment study volume and pricing, the Oncotest, Celsis and Sunrise acquisitions, and higher research model revenue, partly offset by unfavorable foreign currency movements of $5.2 million. The company's year-over-year income tax expense rose to $14.0 million from $0.3 million, reflecting an effective tax rate of 27.1% versus 1.0%, which was affected by a $10.4 million benefit recorded in the prior-year quarter. Cash flow from operations improved to $38.5 million from $11.3 million. Cash and cash equivalents were $157.4 million at quarter end, and total debt was $837.9 million. Subsequent to quarter end, on April 4, 2016, the company acquired WIL Research for a preliminary purchase price of approximately $585.0 million in cash, and on March 30, 2016 it amended its credit facility to $1.65 billion to fund the deal. The company did not repurchase shares under its stock repurchase program during the quarter, leaving $69.7 million available. The filing notes an ongoing patent infringement suit filed by IDEXX Laboratories, for which no loss estimate can be made, and a government billing investigation with about $1.5 million of excess amounts billed recorded as a liability.
- 2015-Q3Nov 4, 2015
Charles River Laboratories International Quarterly Report for Q3 Ended Sep 26, 2015
Charles River Laboratories International, Inc. reported total revenue of $349.5 million for the three months ended September 26, 2015, up from $327.6 million a year earlier, and $1,009.5 million for the nine months, up from $968.1 million. The filing states that foreign currency effects reduced revenue by $18.2 million in the quarter and $56.3 million year to date. Net income attributable to common shareholders was $37.4 million for the quarter (diluted EPS $0.79, versus $0.68) and $117.4 million for the nine months (diluted EPS $2.47, versus $2.09). Operating income rose to $55.4 million for the quarter from $46.2 million, though SG&A increased 18.2% in the quarter, driven partly by acquisition-related costs and stock-based compensation. The company's growth in the period was driven by acquisitions. It bought Celsis in July 2015 for a purchase price of $214.0 million, including assumed debt and certain liabilities, and Sunrise Farms in May 2015 for $9.6 million, which generated a $9.9 million bargain purchase gain. Discovery and Safety Assessment revenue increased 12.4% in the quarter to $158.3 million, while Research Models and Services revenue declined 4.5% to $118.5 million, largely due to currency effects. Goodwill rose to $418.2 million from $321.1 million at year-end 2014, and total assets reached $2.03 billion. Balance sheet leverage increased. Total debt was $825.1 million at September 26, 2015, up from $753.8 million at December 27, 2014, reflecting borrowings under the amended $1.3 billion credit facility. Cash and cash equivalents fell to $74.0 million from $160.0 million. The company repurchased about 1.5 million shares for $108.8 million in the nine months, leaving $69.7 million remaining on its authorization. The filing also discloses a patent infringement complaint by IDEXX Laboratories, which the company intends to defend vigorously, and a government billing investigation with a $1.5 million reserve.
- 2015-Q2Jul 30, 2015
Charles River Laboratories International Quarterly Report for Q2 Ended Jun 27, 2015
Charles River Laboratories International, Inc. reported second-quarter 2015 results for the three months ended June 27, 2015, with total revenue of $339.6 million, essentially flat versus $341.2 million in the prior-year quarter. Revenue was affected by foreign currency: the filing states that reported revenue decreased $20.9 million, or 6.2%, due to negative effects of currency changes. Discovery and Safety Assessment revenue rose to $153.4 million from $142.6 million, while Research Models and Services revenue fell to $120.0 million from $133.1 million. Operating income increased to $55.7 million from $51.0 million, and diluted earnings per share from continuing operations rose to $1.02 from $0.75. Net income attributable to common shareholders was $48.5 million for the quarter, versus $35.3 million a year earlier. The quarter's results were helped by a $9.9 million non-taxable bargain purchase gain on the Sunrise acquisition and an 18.4% effective tax rate. For the six months, total revenue was $660.0 million, up 3.0% from $640.5 million, and net cash provided by operating activities was $97.6 million, compared with $85.4 million. The company amended and restated its credit agreement in April 2015 into a $1.3 billion facility comprising a $400.0 million term loan and a $900.0 million multi-currency revolver, and total debt outstanding was $743.1 million at June 27, 2015. The company repurchased about 1.2 million shares for $90.8 million in the six months, leaving $87.6 million remaining under its authorization. Subsequent to quarter end, on July 24, 2015, the company acquired Celsis International Ltd. for a preliminary purchase price of $212.0 million in cash, to expand its Endotoxin and Microbial Detection business. Cash and cash equivalents were $150.8 million at June 27, 2015, and the company reported that its disclosure controls were effective.
- 2015-Q1Apr 30, 2015
Charles River Laboratories International Quarterly Report for Q1 Ended Mar 28, 2015
Charles River Laboratories International, Inc. reported first-quarter 2015 (three months ended March 28, 2015) total revenue of $320.4 million, up from $299.4 million a year earlier, with the filing noting that revenue would have decreased $17.3 million, or 5.8%, excluding the negative effects of foreign currency exchange rate changes. Discovery and Safety Assessment (DSA) revenue rose $34.8 million, or 33.1%, driven by the Discovery Services business, including the Argenta, BioFocus and ChanTest acquisitions, which contributed $24.1 million to revenue growth. Research Models and Services (RMS) revenue fell $12.5 million, or 9.4%, and Manufacturing Support revenue declined $1.3 million, or 2.1%. Operating income rose to $43.0 million from $39.7 million. Net income attributable to common shareholders was $31.5 million, or $0.66 per diluted share, compared with $32.2 million, or $0.67 per diluted share, a year earlier. Net income was held up by an effective tax rate of 1.0%, versus 24.1% in the prior-year period, which the company attributed mainly to a $10.4 million reduction in unrecognized tax benefits after a statute of limitations expired. Other income (expense), net swung to an $8.3 million expense, reflecting a $10.4 million reversal of an indemnification asset tied to a prior acquisition. On the balance sheet, cash and cash equivalents fell to $151.9 million, and operating cash flow was $11.3 million versus $28.5 million a year earlier. The company repurchased about 0.7 million shares for $50.0 million, leaving $128.5 million remaining on its repurchase authorization. Total debt was $760.1 million at quarter end. Subsequent to the quarter, on April 22, 2015, the company amended and restated its credit facility into a $1.3 billion facility comprising a term loan of approximately $400.0 million and a $900.0 million multi-currency revolving facility, both maturing in April 2020.
- 2014-Q3Oct 30, 2014
Charles River Laboratories International Quarterly Report for Q3 Ended Sep 27, 2014
Charles River Laboratories International, Inc. reported third-quarter 2014 revenue of $327.6 million, up $35.5 million, or 12.2%, from $292.1 million a year earlier, with $0.4% of that growth attributed to foreign currency translation benefit. Operating income rose $5.4 million, or 13.2%, to $46.2 million, and diluted earnings per share from continuing operations were $0.68 versus $0.64. Growth was driven mainly by the Discovery and Safety Assessment (DSA) segment, where revenue increased $28.3 million, or 25.1%, largely due to the April 1, 2014 Early Discovery acquisition, which contributed $23.3 million of revenue in the quarter. Amortization of intangibles rose 81.0% to $7.6 million, which partly offset operating gains in the DSA segment. For the nine months ended September 27, 2014, revenue rose $91.8 million, or 10.5%, to $968.1 million, and operating income increased $10.1 million, or 8.0%, to $136.9 million. Net cash provided by operating activities was $152.3 million, while investing outflows of $217.2 million were mainly the $183.1 million net cash cost of the Early Discovery acquisition. Total debt increased to $769.6 million from $663.0 million at year-end 2013, and the company repurchased $122.0 million of treasury stock in the nine-month period. Cash and cash equivalents were $130.7 million at quarter end, and remaining authorization under the stock repurchase program was $28.5 million. The filing also discloses a subsequent event: on October 29, 2014, the company acquired ChanTest Corporation for a preliminary purchase price of $52.0 million in cash plus up to $2.0 million of contingent consideration. The company also reported a $1.5 million reserve related to inaccurate government contract billings and stated it cannot estimate losses beyond that reserve, and disclosed an effective tax rate of 26.2% for the nine months.
- 2014-Q2Aug 7, 2014
Charles River Laboratories International Quarterly Report for Q2 Ended Jun 28, 2014
Charles River Laboratories International, Inc. reported total revenue of $341.2 million for the three months ended June 28, 2014, up from $292.9 million a year earlier, a 16.5% increase. The filing states that the April 1, 2014 Early Discovery acquisition contributed $23.5 million of that revenue. Operating income rose to $51.0 million from $43.2 million, and net income attributable to common shareholders was $35.3 million, or $0.74 per diluted share, versus $0.56 a year earlier. For the six months, revenue was $640.5 million and net income attributable to common shareholders was $67.5 million, or $1.41 per diluted share. The company revised its reportable segments to Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support, effective this quarter with retrospective recasting. DSA revenue grew 32.7% in the quarter, largely from Early Discovery, while RMS revenue rose 2.6% and manufacturing revenue rose 17.6%. Corporate SG&A increased 23.6% for the quarter, which the filing attributes mainly to acquisition evaluation and integration costs, compensation, and consulting. Balance sheet and cash flow changes were significant. Total assets reached $1.86 billion at June 28, 2014, versus $1.63 billion at December 28, 2013, and total debt rose to $802.8 million. Cash used in investing activities was $202.5 million, mainly for the Early Discovery acquisition, and the company repurchased $101.6 million of treasury stock in the six months, leaving $48.8 million remaining under its stock repurchase program. The filing also discloses a $1,500 thousand reserve for inaccurate government contract billings and an arbitration award of $1.2 million, plus costs and interest, to a large animal model supplier.
- 2014-Q1Apr 30, 2014
Charles River Laboratories International Quarterly Report for Q1 Ended Mar 29, 2014
Charles River Laboratories International, Inc. reported first-quarter 2014 total revenue of $299.4 million, up 2.8% from $291.2 million a year earlier, with growth in both segments. Research Models and Services (RMS) revenue rose 1.7% to $185.6 million, while Preclinical Services (PCS) revenue rose 4.7% to $113.8 million. Gross margin improved to 36.3% from 35.8%, but operating income fell 7.2% to $39.7 million, driven mainly by higher unallocated corporate costs tied to acquisition evaluation and integration and by charges from global efficiency initiatives, including the planned closure of the Portage, Michigan research model facility. Net income attributable to common shareholders increased 25.8% to $32.2 million, helped by lower interest expense ($2.8 million versus $8.3 million) and $5.9 million of other income, largely from venture capital limited partnership gains of $6.1 million. Cash flow from operations was $28.5 million versus $30.0 million a year earlier. Cash and cash equivalents were $169.9 million at March 29, 2014, and total debt was $640.1 million. The company repurchased 183,300 shares for $9.8 million under its program, with $129.3 million remaining on the authorization. Subsequent to quarter end, on April 1, 2014, the company acquired the CRO services division of Galapagos N.V. (Argenta and BioFocus businesses) for a preliminary cash purchase price of $190.7 million plus up to $6.9 million in contingent consideration, funded with about $75 million of cash on hand and $116 million of revolver borrowings. The filing also discloses a government contract billing matter with a $1.5 million reserve, where the company says it cannot estimate losses beyond that reserve, and a Mauritius arbitration over a large animal model supply agreement where no loss estimate can be made.
- 2013-Q3Oct 30, 2013
Charles River Laboratories International Quarterly Report for Q3 Ended Sep 28, 2013
Charles River Laboratories International, Inc. reported third-quarter 2013 net sales of $292.1 million, up 4.8% from $278.7 million a year earlier, with operating income of $40.8 million (14.0% of net sales) versus $37.7 million. Diluted EPS was $0.64 compared with $0.46 in the prior-year quarter. The filing attributes the margin improvement largely to tax-related items, including the settlement of a Canadian tax audit and a U.K. tax law change, along with favorable preclinical study mix, partially offset by accelerated depreciation tied to the consolidation of U.S. research model production. Nine-month net sales were $876.3 million, and net income attributable to common shareholders was $83.7 million. Balance sheet and cash flow activity were shaped by refinancing. On May 29, 2013, the company entered into a new $970 million credit facility, with a $420 million U.S. term loan and a $550 million revolver, and used it to retire its $350 million 2.25% Senior Convertible Debentures due June 2013. Total debt was $639.7 million at September 28, 2013, versus $666.4 million at year-end 2012. Cash and equivalents rose to $130.5 million, and operating cash flow for the nine months was $146.6 million. The company repurchased $93.1 million of stock in the nine months, and the board raised the repurchase authorization to $850 million from $750 million. The filing also discloses an internal investigation into inaccurate billing on certain government contracts, with a $1.5 million reserve, and states that Item 4 concluded disclosure controls were not effective because of a material weakness identified as of December 29, 2012. Management stated that additional procedures support the reliability of the financial statements, and remediation efforts were ongoing.
- 2013-Q2Jul 31, 2013
Charles River Laboratories International Quarterly Report for Q2 Ended Jun 29, 2013
Charles River Laboratories International, Inc. reported net sales of $292.9 million for the three months ended June 29, 2013, an increase of $8.2 million, or 2.9%, from $284.7 million a year earlier, with growth in both the Research Models and Services (RMS) and Preclinical Services (PCS) segments. Operating income declined to $43.2 million from $49.3 million, a decrease of 12.4%, due primarily to lower operating income in RMS, where lower legacy research model sales and an adjustment tied to inaccurate government billings weighed on margins. Net income attributable to common shareholders was $27.3 million, or $0.56 diluted EPS, versus $30.5 million and $0.63 a year earlier. For the six months, net sales were $584.2 million, up 2.4%, and net income attributable to common shareholders was $52.9 million. The balance sheet and financing activity were shaped by the May 29, 2013 refinancing into a $970 million credit facility ($420.0 million term loan and $550.0 million revolver, maturing May 2018), which was used to retire the $350.0 million 2.25% Senior Convertible Debentures that matured in June 2013. Total debt was $635.2 million at June 29, 2013, versus $666.4 million at December 29, 2012. The company also acquired a 75% interest in Vital River, a China research models provider, for approximately $26.9 million, and the Board increased the stock repurchase authorization to $850.0 million from $750.0 million on July 30, 2013. The filing discloses a material weakness in internal control over financial reporting as of December 29, 2012, related to information technology business processes, and states that disclosure controls were not effective as of June 29, 2013. Management also disclosed an investigation into inaccurate billing on certain government contracts, with approximately $1.5 million in excess amounts billed since January 1, 2007 reserved, and noted that the company cannot yet estimate a range of loss beyond that reserve.
- 2013-Q1May 8, 2013
Charles River Laboratories International Quarterly Report for Q1 Ended Mar 30, 2013
Charles River Laboratories International, Inc. reported net sales of $291.2 million for the first quarter ended March 30, 2013, an increase of $5.2 million, or 1.8%, from $286.0 million a year earlier. The increase was driven mainly by the Preclinical Services (PCS) segment, which grew 5.8% to $108.7 million, partially offset by lower Research Models and Services (RMS) sales, which declined 0.4% to $182.5 million. Foreign currency translation reduced sales by 1.0%. Operating income was $42.8 million, down from $43.7 million, and the operating margin fell to 14.7% from 15.3%. Net income attributable to common shareowners was $25.6 million, or $0.53 diluted EPS, compared with $26.4 million, or $0.54, in the prior-year quarter. The company completed the acquisition of a 75% interest in Vital River, a China-based research models provider, for approximately $26.9 million in cash in January 2013. Cash and cash equivalents fell to $100.4 million from $109.7 million at year-end, reflecting share repurchases, capital expenditures and debt prepayments. Total debt was $648.2 million, including $350.0 million of 2.25% Senior Convertible Debentures due June 2013, whose fair value was about $353.1 million. Management stated it expects to settle these notes using cash, the credit facility and other financing alternatives. The filing also discloses that management concluded disclosure controls were not effective as of December 29, 2012 because of a material weakness in IT business process and financial reporting controls. Management described remediation steps begun in the first quarter of 2013 and stated that the financial statements for the period are fairly stated in all material respects.
- 2012-Q3Nov 1, 2012
Charles River Laboratories International Quarterly Report for Q3 Ended Sep 29, 2012
Charles River Laboratories International, Inc. filed this Form 10-Q for the quarter ended September 29, 2012. Net sales for the third quarter were $278.7 million, up 0.4% from $277.6 million a year earlier, with Preclinical Services sales rising 5.7% offset by foreign currency translation that reduced sales by 3.2%. Operating income was $37.7 million (13.5% of net sales) versus $37.1 million a year earlier. Net income attributable to common shareowners was $22.0 million, or $0.46 diluted EPS, compared with $18.8 million and $0.37 in the prior-year quarter. For the nine months, net sales were $849.4 million (down 0.3%), operating income was $130.7 million (down 1.5%, reflecting a prior-year $7.7 million insurance gain), and diluted EPS was $1.63 versus $1.58. The Research Models and Services segment's third-quarter operating margin fell to 26.1% from 28.3%, while Preclinical Services' operating margin improved to 9.8% from 3.5%, driven by higher safety assessment demand. Management cited a strategic partnership with AstraZeneca as a notable win. Balance sheet items to note include $125.6 million of current debt, which includes $101.8 million of the 2.25% Senior Convertible Debentures due June 2013, and $349,995 thousand of those notes in principal. Cash rose to $83.2 million, and operating cash flow for the nine months was $143.7 million, against $35.2 million used in investing activities, including $33.8 million of capital expenditures and a $16.9 million acquisition (Accugenix). Share repurchases totaled $45.8 million for the nine months. Subsequent to quarter-end, the company agreed in October 2012 to acquire a 75% interest in Vital River, a China-based research models provider, for approximately $27 million in cash, with closing expected in the first quarter of 2013. Management expects 2012 capital expenditures of about $50.0 million.
- 2012-Q2Aug 7, 2012
Charles River Laboratories International Quarterly Report for Q2 Ended Jun 30, 2012
Charles River Laboratories International, Inc. reported net sales of $284.7 million for the three months ended June 30, 2012, a decrease of $3.6 million, or 1.2%, from $288.3 million a year earlier, which the filing attributes primarily to unfavorable foreign currency translation of 3.1%. Operating income was $49.3 million compared with $53.3 million, a decrease the filing attributes primarily to a prior-year insurance gain of $7.7 million, unfavorable foreign exchange and lower gross margin, partly offset by an insurance settlement related to last year's disaster on Japan operations. Net income attributable to common shareowners was $30.5 million, or $0.63 diluted EPS, versus $32.3 million and $0.63 a year earlier. For the six months, net sales were $570.7 million, down 0.6%, and diluted EPS from continuing operations was $1.17 versus $1.30 in the prior-year period. Cash flow and balance sheet activity show net cash provided by operating activities of $82.6 million for the six months, versus $86.7 million, and capital expenditures of $23.6 million, with management expecting about $50.0 million for the year. Total debt was $686.2 million at June 30, 2012, including $350.0 million of 2.25% Senior Convertible Debentures due June 2013, of which the filing says $100.7 million is classified as current. The company repurchased 889,791 shares for $30.8 million in the first half, and the filing states that the company was compliant with all financial covenants under its credit agreement. Segment results show Research Models and Services net sales of $173.6 million in the quarter (down 2.6%) with operating income of $55.5 million, while Preclinical Services net sales rose 0.9% to $111.1 million with operating income of $10.8 million. The filing reports that the company is pursuing four initiatives: improving operating margin, improving free cash flow, investing in growth businesses, and returning value to shareholders.
- 2012-Q1May 4, 2012
Charles River Laboratories International Quarterly Report for Q1 Ended Mar 31, 2012
Charles River Laboratories International, Inc. reported net sales of $285,981 thousand ($286.0 million) for the three months ended March 31, 2012, an increase of $0.2 million, or 0.1%, from $285.8 million in the prior-year quarter. Net sales for the Research Models and Services (RMS) segment rose 5.6% to $183.2 million, while Preclinical Services (PCS) sales fell 8.6% to $102.8 million. Operating income was $43.7 million, up from $42.3 million, and operating margin improved to 15.3% from 14.8%. Net income attributable to common shareowners was $26.4 million, or $0.54 per diluted share, compared with $31.3 million, or $0.57 per diluted share, a year earlier. The prior-year figure was boosted by an $11.1 million tax benefit tied to the disposition of the Phase I clinical business, and the effective tax rate rose to 24.7% from a benefit of (8.3)%. Cash flow from operations was $25.3 million, compared with $21.4 million in the prior-year quarter, while capital expenditures were $14.1 million. The company repurchased 347,968 shares for $12.5 million under open market purchases and reported cash and cash equivalents of $61.0 million at March 31, 2012. Total debt was $704.3 million, including $350.0 million of 2.25% Senior Convertible Debentures due June 2013, which the company intends to settle in cash at maturity using existing cash, operating cash flow, and its credit agreement capacity. Management stated that the company's market appears to be stabilizing, but it remains uncertain when unfavorable market factors will abate. The company also expects 2012 capital expenditures of approximately $50.0 million. For the quarter, the company remained in compliance with all financial covenants in its credit agreement. Management described continued customer caution, pricing pressure, and a shift toward non-GLP discovery services within PCS, which reduced that segment's operating margin to 4.1% from 8.3%.
- 2011-Q3Nov 2, 2011
Charles River Laboratories International Quarterly Report for Q3 Ended Sep 24, 2011
Charles River Laboratories International, Inc. reported third-quarter 2011 total net sales of $277.6 million, up 2.5% from $270.9 million a year earlier, with the filing attributing the increase primarily to higher Research Models and Services (RMS) sales, partly offset by lower Preclinical Services (PCS) demand from reduced biopharmaceutical spending. Operating income rose to $37.1 million from $6.5 million, a year-earlier period that included a $30.0 million WuXi termination fee. Net income attributable to common shareowners was $18.8 million, or $0.37 diluted EPS, compared with a loss of $24.9 million in the prior-year quarter. The effective tax rate was 22.9%, reflecting a $1.4 million benefit from the settlement of a German tax audit. For the nine months, net sales were $851.7 million, essentially flat year over year, and operating income more than doubled to $132.7 million, aided by a $7.7 million life insurance gain and lower SG&A. Diluted EPS from continuing operations was $1.69 for the nine months. Cash and cash equivalents declined to $81.2 million from $179.2 million at year-end 2010, reflecting $255.6 million in treasury stock purchases and a net debt increase; total debt and capital leases rose to $740.3 million. Operating cash flow was $134.9 million for the nine months, up from $100.8 million. Management continues its four initiatives, including margin improvement and shareholder returns. The company disclosed a headcount reduction of approximately 2%, primarily in PCS, expected to produce annual savings of about $7.5 million beginning in 2012 with roughly $3.5 million of severance and other costs in the fourth quarter of 2011. As of September 24, 2011, $141 million remained under the $750.0 million stock repurchase authorization, and the company amended its credit agreement, extending maturity to September 2016.
- 2011-Q2Aug 3, 2011
Charles River Laboratories International Quarterly Report for Q2 Ended Jun 25, 2011
Charles River Laboratories International, Inc. reported net sales of $288.3 million for the three months ended June 25, 2011, essentially flat against $288.6 million a year earlier. Operating income rose to $53.3 million from $30.0 million, supported by higher gross margin (36.9% of net sales versus 34.9%), a $7.7 million life insurance gain and a $7.3 million prior-year cost associated with evaluating acquisitions. Net income attributable to common shareowners was $32.3 million, or $0.63 diluted, compared with $14.5 million, or $0.22, a year earlier. Results were also helped by a lower effective tax rate of 20.2%, versus 32.0% a year earlier. For the six months ended June 25, 2011, net sales were $574.1 million, down 1.2%, as lower Preclinical Services demand offset growth in Research Models and Services. Operating income was $95.6 million, up from $60.2 million, and net income attributable to common shareowners was $63.7 million. Cash flow from operations was $86.7 million for the six months, while the company repurchased $191.1 million of treasury stock and ASR shares and increased total debt and capital leases to $789.4 million. The company's stated four initiatives are improving operating margin, improving free cash flow, disciplined investment in growth businesses and returning value to shareholders, with $205.0 million remaining under its $750.0 million repurchase authorization at quarter end. Management states that the market appears to be stabilizing but remains uncertain about when unfavorable market factors will abate, and it notes that predicting the timing of demand recovery for preclinical services is challenging. The company also disclosed ongoing tax disputes in Germany and Canada, auction rate securities of $11.2 million that remain illiquid, and a Japan-related risk factor following the March 2011 earthquake and tsunami.
- 2011-Q1May 4, 2011
Charles River Laboratories International Quarterly Report for Q1 Ended Mar 26, 2011
Charles River Laboratories International, Inc. reported total net sales of $285.8 million for the three months ended March 26, 2011, a decrease of $6.5 million, or 2.2%, from $292.3 million in the prior-year quarter. Operating income rose to $42.3 million from $30.2 million, an increase of 39.9%, with operating margin of 14.8% versus 10.3%, driven mainly by cost-savings actions and lower operating expenses. Net income attributable to common shareowners was $31.3 million, or $0.57 per diluted share, compared with $17.4 million, or $0.26 per diluted share, a year earlier. The quarter benefited from an $11.1 million tax benefit tied to the disposal of the Phase I clinical business on March 28, 2011, which produced an effective tax rate of (8.3)%. The Preclinical Services segment sales fell 6.3% to $112.5 million, while operating income rose to $9.3 million from $0.4 million. Research Models and Services sales rose 0.7% to $173.4 million, with operating income up to $51.7 million. Management said the market appears to be stabilizing but remains uncertain about when unfavorable factors will abate. Capital allocation was a major focus. The company repurchased $174.5 million of treasury stock and ASR-related shares, including a $150.0 million accelerated stock repurchase entered into February 24, 2011. Total debt and capital leases rose to $856.8 million from $700.9 million, largely from a $150.0 million incremental U.S. term loan under an amended $900.0 million credit agreement. Cash and cash equivalents fell to $158.7 million, and operating cash flow was $21.4 million versus $27.9 million a year earlier.
- 2010-Q3Nov 4, 2010
Charles River Laboratories International Quarterly Report for Q3 Ended Sep 25, 2010
Charles River Laboratories International, Inc. reported a sharply weaker third quarter of 2010, with total net sales of $276.1 million, down 7.2% from $297.5 million a year earlier, and a net loss attributable to common shareowners of $24.9 million, or $(0.40) per diluted share, versus net income of $37.3 million ($0.57 per diluted share) in the prior-year quarter. The decline was driven by lower demand and pricing for Preclinical Services (PCS), which fell 12.9%, and a $30.0 million termination fee paid to WuXi PharmaTech upon terminating the previously announced acquisition agreement. Operating income fell to $5.1 million from $44.4 million, and interest expense rose to $12.7 million from $5.6 million. The income tax provision was $16.3 million on a pre-tax loss, reflecting the non-deductible termination fee and costs to repatriate approximately $205.4 million of non-U.S. earnings. For the nine months, net sales were $865.5 million, down 4.6%, and net income attributable to common shareowners was $6.9 million, or $0.11 per diluted share, compared with $96.9 million ($1.47) a year earlier. Capital allocation changed materially during the period: the company paid $300.0 million under an accelerated share repurchase program, bought back 1,759,857 additional shares on the open market for $52.9 million, and increased its credit facility to $750.0 million, which lifted total debt and capital leases to $718.9 million at September 25, 2010 from $492.8 million at December 26, 2009. Cash and cash equivalents declined to $137.4 million, and shareowners' equity fell to $1.04 billion from $1.38 billion. Management also announced fourth-quarter 2010 actions, including a headcount reduction of about 4%, a facility closure in Laval, Quebec, and consolidation of a Michigan operation, expected to generate annual savings of approximately $40.0 million beginning in 2011 against a one-time charge of approximately $15.0 million.
- 2010-Q2Aug 3, 2010
Charles River Laboratories International Quarterly Report for Q2 Ended Jun 26, 2010
Charles River Laboratories International, Inc. reported second-quarter 2010 total net sales of $292.1 million, a decrease of 5.2% from $308.2 million a year earlier, and net income attributable to common shareowners of $14.5 million, or $0.22 diluted EPS, compared with $34.2 million and $0.52 in the prior-year quarter. Operating income fell to $28.2 million from $50.7 million, a decrease of 44.3%, and operating margin declined to 9.7% from 16.4%. The filing attributes the sales decline mainly to lower pricing and slower demand in Preclinical Services (PCS), where segment sales fell 12.3% in the quarter, and to reduced biopharmaceutical spending. Research Models and Services (RMS) sales rose 0.9% in the quarter, to $167.1 million. For the six months, net sales were $589.4 million, down 3.3%, and diluted EPS was $0.48 versus $0.91. The company recorded $4.8 million of severance related to suspending operations at its Shrewsbury, Massachusetts PCS facility, and it notes that interest expense rose to $13.1 million for the six months, partly due to a commitment fee tied to the WuXi financing. Cash and cash equivalents were $219.1 million at June 26, 2010, up from $182.6 million at December 26, 2009, while operating cash flow fell to $83.8 million from $107.3 million, with days sales outstanding rising to 51 days. Subsequent to quarter-end, on July 29, 2010, the company agreed to terminate its acquisition agreement with WuXi PharmaTech (Cayman) Inc. in exchange for a $30 million breakup fee, canceling the August 5, 2010 special stockholder meeting. The board also authorized a new $500 million stock repurchase program, replacing a prior $600 million authorization.